Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab;Respuesta a la suspensión de azatioprina en pacientes con enfermedad de Crohn en terapia combinada con infliximab

Anales de Pediatria

Volumn 70, Issue 3, 2009, Pages 271-277

  Martin De Carpi J ^a   Varea, V ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Azathioprine; Combined therapy; Hepatosplenic T cell lymphoma; Infliximab; Paediatric Crohn's disease

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CLINICAL EVALUATION; CROHN DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; MONOTHERAPY; SCHOOL CHILD; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 62749148265     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2008.09.014     Document Type: Article

References (22)

1. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colomber Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet. 359 2002 1541 1549
2. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, and J. Johanns Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med. 353 2005 2462 2476
3. J.F. Colombel, E.V. Loftus Jr, W.J. Tremaine, L.J. Egan, W.S. Harmsen, and C.D. Schleck The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients Gastroenterology. 126 2004 19 31
4. W.V. Crandall, and L.M. Mackner Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model Aliment Pharmacol Ther. 17 2003 75 84
5. P. Rutgeerts, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colombel Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology. 126 2004 402 413
6. S. Vermeire, M. Norman, G. Van Assche, F. Baert, G. D'Haens, and P. Rutgeerts Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut. 56 2007 1226 1231
7. J. Punaty, J. Markowitz, T. Lerer, J. Hyams, S. Kugathasan, and A. Griffiths Effect of early immunomodulator use in moderate to severe pediatric Crohn disease Inflamm Bowel Dis. 14 2008 949 954
8. S. Kugathasan, S.L. Werlin, A. Martínez, M.T. Rivera, J.B. Heikenen, and D.G. Binion Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease Am J Gastroenterol. 95 2000 3189 3194
9. O. Borrelli, C. Bascietto, F. Viola, M. Bueno de Mesquita, M. Barbato, and V. Mancini Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease Dig Liver Dis. 36 2004 342 347
10. T.D. Walters, A.R. Gilman, and A.M. Griffiths Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease Inflamm Bowel Dis. 13 2007 424 430
11. J. Martín de Carpi, L. Masiques, R. García Romero, C. Acuña, C. Bernal, and S. Pinillos Top-down therapy with infliximab and azathioprine in newly diagnosed paediatric Crohn's disease J Pediatr Gastroenterol Nutr. 43 Suppl 2 2006 S42
12. A. Kandiel, A.G. Fraser, B.I. Korelitz, C. Brensinger, and J.D. Lewis Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut. 54 2005 1121 1125
13. D. Palli, G. Trallori, S. Bagnoli, C. Saieva, O. Tarantino, and M. Ceroti Hodgkin's disease risk is increased in patients with ulcerative colitis Gastroenterology. 119 2000 647 653
14. C. Bernstein, J. Blanchard, E. Kliewer, and A. Wajda Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer. 91 2001 854 862
15. J.L. Jones, and E.V. Loftus Jr Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 13 2007 1299 1307
16. A.C. Mackey, L. Green, L.C. Liang, P. Dinndorf, and M. Avigan Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease J Pediatr Gastroenterol Nutr. 44 2007 265 267
17. Shale M, Kanfer E, Panaccione, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 2008 [Epub ahead of print]; doi:10.1136/gut. 2008.163279.
18. US Food and Drug Administration center for drug evaluation and research website [citado 18 Ago 2008]. Disponible en: http://fda.gov/cder/aers/anti-TNF.
19. K.A. Frankolla, A. Altman, and F.A. Silvester Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab J Pediatr Gastroenterol Nutr. 47 2008 193 195
20. G. Van Assche, C. Magdelaine-Beuzelin, G. D'Haens, F. Baert, M. Noman, and S. Vermeire Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Gastroenterology. 134 2008 1861 1868
21. Martín de Carpi J, Vilar P, Varea V. Infliximab como terapia de rescate en colitis ulcerosa grave resistente al tratamiento corticoideo. An Pediatr (Barc). 2009 2008;69:351-4.
22. D.A. Jacobstein, J.E. Markowitz, B.S. Kirschner, G. Ferry, S.A. Cohen, and B.D. Gold Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium Inflamm Bowel Dis. 11 2005 442 446